Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Capacity Expansion

Kabra Drugs Capacity Expansion

Kabra Drugs Limited announced strategic expansion into pharmaceutical manufacturing and AI-integrated defense technologies. Key initiatives include establishing an R&D facility at Cactus TECCI Park, Chennai, and obtaining a SCOMET license. The company also appointed Mr. Alagiamanavalan as an Independent Consultant for defense projects to drive diversification and long-term value creation.

Key figures
Execution periodPhase 1 focusing on South India; project implementation initiated immediately
Source

BSE filing, NSE: KABRADG. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Kabra Drugs Ltd: key numbers

Share price
₹16.26
Market cap
₹38.55 Cr
Revenue (annual)
₹92.74 Cr
Net profit (annual)
₹4.96 Cr
P/E (TTM)
5.1×Sector 46.1×
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Kabra Drugs Ltd

All →

Other capacity expansion announcements

All →